AbCellera Biologics Inc (NASDAQ:ABCL) currently has a daily average trading volume of 2.22M but it saw 4471453 shares traded in last market. With a market cap of 794.53M USD, the company’s current market price of $2.69 came falling about -3.58 while comparing to the previous closing price of $2.79. In past 52 weeks, the stock remained buoying in the range of price level as high as $6.05 and as low as $2.34. In the recent trading on the day, stock has struck highest price mark of $2.66 while lowest mark touched by it was $2.835.
Taking a look at 20-day trading activity of AbCellera Biologics Inc (ABCL) gives us an average price of $2.88, while its current price level is -55.57% below from 52-week high level whereas it is 15.20% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.80 while that of 200 days or SMA-200 reads an average of $3.25. A closer look into the stock’s movement over the week reveals that its volatility is standing at 7.33% during that period while stretching the period over a month that decreases to 5.75%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 42.74 which implies that the stock is in neutral territory.
The Benchmark Company upgraded its recommendation for the stock as a “Buy” from “Hold” on February 22, 2024 while assigning a price target of $9. KeyBanc Capital Markets issued its recommendations for the stock as it initiated the price target for the stock is $6.
Over the week, ABCL’s stock price is moving -7.56% down while it is 1.51% when we observe its performance for the past one month. Year-to-date it is -52.89% down and over the past year, the stock is showing a downside performance of -49.44%.
Currently, AbCellera Biologics Inc’s total number of outstanding shares is 295.16M. Company’s return on investment (ROI) stands at -15.36% and return on equity (ROE) at -15.55%. Stock’s beta reads 0.41. Stock has a price to book (P/B) ratio of 0.74 while price to sale or P/S ratio amounts to 24.11. Its return on asset (ROA) is -12.10% on average.
